Biopharmx Corporatio (BPMX) 2.2500 $BPMX
BioPharmX Corporation Files Registration Statement For Proposed Public Offering
PR Newswire - Thu Apr 09, 4:37PM CDT
BioPharmX Corporation (OTCQB: BPMX), a specialty pharmaceutical company focused on the development of proprietary drug delivery products, today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed public offering of its common stock. The number of shares to be offered by BioPharmX and the price range for the offering have not yet been determined.
BioPharmX Corporation Appoints Stephen Morlock To Its Board Of Directors
PR Newswire - Mon Mar 30, 8:30AM CDT
BioPharmX Corporation (OTCQB: BPMX), a specialty pharmaceutical company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced the appointment of Stephen Morlock, a seasoned financial executive and retail industry veteran, to its board of directors. Mr. Morlock's background will assist the company as it continues to expand its national roll-out of Violet iodine, the new, once-daily, non-prescription pill for relief of premenstrual breast discomfort, and he will serve as an independent board member on BioPharmX Corporation's audit, compensation and nominating and corporate governance committees.
BioPharmX Corporation Completes Pre-IND Meeting With U.S. FDA To Review Its Topical Acne Solution
PR Newswire - Wed Mar 18, 7:00AM CDT
BioPharmX Corporation (OTCQB: BPMX), a specialty pharmaceutical company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that its planned pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) was held on March 11, 2015, as scheduled. The pre-IND meeting focused on the company's topical antibiotic acne compound currently under development and the company's proposed strategy for advancing its acne program and plans for conducting safety and toxicology studies, along with human clinical trials.
BioPharmX Announces Violet(TM) Iodine Now Available at Leading National Retailer
PR Newswire - Tue Mar 10, 7:00AM CDT
BioPharmX Corporation (OTCQB: BPMX), makers of Violet(TM) iodine, the new, once-daily, non-prescription pill for the relief of premenstrual breast discomfort, today announced the first-of-its-kind product has added a major U.S. drugstore chain to its retail partners. The daily supplement is available now and will be offered exclusively in the feminine care aisle.
BioPharmX names Michael Hubbard as chair of audit committee
M2 - Fri Jan 30, 2:10AM CST
Biotechnology company BioPharmX (OTCBB:BPMX) disclosed on Wednesday the addition of Michael Hubbard as a new independent member of its board of directors, increasing the board's total number of members to four.
BioPharmX Corporation Appoints Michael Hubbard To Its Board Of Directors
PR Newswire - Wed Jan 28, 10:30AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced the appointment of Michael Hubbard as a new independent member of its board of directors. Hubbard, a seasoned financial executive with a career in public accounting and auditing, will also lead the company's audit committee. Hubbard's appointment brings the board's total number of members to four.
BioPharmX Corporation Granted Pre-IND Meeting With U.S. FDA To Review Its Topical Acne Solution
PR Newswire - Mon Jan 12, 9:00AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has been granted a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration to discuss the company's topical antibiotic acne compound currently under development. The meeting, currently scheduled for March 2015, is expected to focus on the company's proposed strategy for advancing its acne program and plans for conducting safety and toxicology studies, along with human clinical trials.
BioPharmX Corporation To Present At OneMed Forum SF 2015 Conference
PR Newswire - Thu Jan 08, 9:00AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that Jim Pekarsky, chief executive officer and co-founder of BioPharmX, will present at the OneMed Forum SF 2015 Conference on Monday, January 12 at 3:00 p.m. PST at the Marriott Marquis in San Francisco.
UPM Pharmaceuticals to Manufacture BioPharmX's First Commercially Available Product
PR Newswire - Wed Dec 10, 8:00AM CST
UPM Pharmaceuticals, a division of Gregory Pharmaceutical Holdings, Inc., has reached an agreement with BioPharmX, Inc. (OTCQB: BPMX) to commercially manufacture solid dose iodine supplement tablets for the consumer products sector. The tablets will be manufactured at UPM's 475,000 square-foot manufacturing facility in Bristol, Tennessee, under a commercial supply agreement. Terms of the agreement were not disclosed.
BioPharmX unveils Violet iodine for relief of premenstrual breast discomfort and symptoms associated with Fibrocystic Breast Condition
M2 - Wed Dec 10, 6:27AM CST
Biotechnology company BioPharmX (OTCBB:BPMX) disclosed on Tuesday the market launch of its new, once-daily pill for relief of premenstrual breast discomfort, Violet iodine.
Introducing Violet(TM) Iodine, New Once-Daily, Non-Prescription Pill For Relief Of Premenstrual Breast Discomfort*
PR Newswire - Tue Dec 09, 8:37AM CST
BioPharmX Corporation (OTCQB: BPMX) today announced the availability of VioletTM iodine, a new, once-daily pill for relief of premenstrual breast discomfort. The first-of-its-kind product is based on the latest molecular iodine technology designed to help free women from the burden of breast discomfort by addressing the underlying causes of a condition known as fibrocystic breast condition (FBC), with the added benefit of promoting breast health for women of reproductive age.*
BioPharmX Corporation Announces Submission Of Pre-IND Meeting Request To The U.S. FDA For Its Topical Acne Solution
PR Newswire - Tue Dec 02, 6:30AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company's topical antibiotic acne compound currently under development. The company plans to follow up by submitting a briefing package on a later date in support of a pre-IND meeting to review the company's proposed strategy and plan for conducting safety and toxicology studies and human clinical trials required for approval of its acne product.
BiopharmX Announces Breast Health Medical Advisory Board
PR Newswire - Mon Nov 17, 7:00AM CST
BioPharmX Corporation (OTCQB: BPMX) today announced the formation of a Breast Health Medical Advisory Board (MAB) composed of highly respected physicians selected to provide a depth and range of experience in breast health. Members will serve as a strategic resource to BioPharmX as it develops products that address unmet breast health needs. Specifically, the advisory board will provide clinical trial and protocol design advice and guidance regarding emerging breast health trends and new product opportunities.
BioPharmX Corporation Announces Appointment Of Ping Wang Of Korea Investment Partners To Board Of Directors
PR Newswire - Mon Nov 10, 7:10AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced the appointment of Mr. Ping Wang, Principal of Korea Investment Partners, to the company's board of directors. Mr. Wang's appointment follows Korea Investment Partners' investment in BioPharmX as part of its Series A private placement, which was also announced today.
BioPharmX Corporation Secures Up To $12 Million In Private Placement
PR Newswire - Mon Nov 10, 7:00AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, announced that the Company has secured up to $12 million in a Series A private placement (Series A). The $12 million in total funding secured includes convertible notes previously converted to common shares, as well as the Series A private placement, which was completed in a series of closings that occurred between May 2014 and November 2014. The total amount includes $2 million in funding subject to the company achieving certain milestones. The proceeds are being used to advance the Company's pipeline of products in the fields of women's health and dermatology and to fund the near-term launch and commercialization of the Company's women's health product. The Series A private placement was led by Korea Investment Partners (KIP), which is now represented on BioPharmX's board of directors, and complemented by a combination of accredited institutional investors and high-net worth private individuals.
BioPharmX Corporation Files Registration Statement For Proposed Public Offering
PR Newswire - Thu Apr 09, 4:37PM CDT
BioPharmX Corporation (OTCQB: BPMX), a specialty pharmaceutical company focused on the development of proprietary drug delivery products, today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed public offering of its common stock. The number of shares to be offered by BioPharmX and the price range for the offering have not yet been determined.
BioPharmX Corporation Appoints Stephen Morlock To Its Board Of Directors
PR Newswire - Mon Mar 30, 8:30AM CDT
BioPharmX Corporation (OTCQB: BPMX), a specialty pharmaceutical company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced the appointment of Stephen Morlock, a seasoned financial executive and retail industry veteran, to its board of directors. Mr. Morlock's background will assist the company as it continues to expand its national roll-out of Violet iodine, the new, once-daily, non-prescription pill for relief of premenstrual breast discomfort, and he will serve as an independent board member on BioPharmX Corporation's audit, compensation and nominating and corporate governance committees.
BioPharmX Corporation Completes Pre-IND Meeting With U.S. FDA To Review Its Topical Acne Solution
PR Newswire - Wed Mar 18, 7:00AM CDT
BioPharmX Corporation (OTCQB: BPMX), a specialty pharmaceutical company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that its planned pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) was held on March 11, 2015, as scheduled. The pre-IND meeting focused on the company's topical antibiotic acne compound currently under development and the company's proposed strategy for advancing its acne program and plans for conducting safety and toxicology studies, along with human clinical trials.
BioPharmX Announces Violet(TM) Iodine Now Available at Leading National Retailer
PR Newswire - Tue Mar 10, 7:00AM CDT
BioPharmX Corporation (OTCQB: BPMX), makers of Violet(TM) iodine, the new, once-daily, non-prescription pill for the relief of premenstrual breast discomfort, today announced the first-of-its-kind product has added a major U.S. drugstore chain to its retail partners. The daily supplement is available now and will be offered exclusively in the feminine care aisle.
BioPharmX names Michael Hubbard as chair of audit committee
M2 - Fri Jan 30, 2:10AM CST
Biotechnology company BioPharmX (OTCBB:BPMX) disclosed on Wednesday the addition of Michael Hubbard as a new independent member of its board of directors, increasing the board's total number of members to four.
BioPharmX Corporation Appoints Michael Hubbard To Its Board Of Directors
PR Newswire - Wed Jan 28, 10:30AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced the appointment of Michael Hubbard as a new independent member of its board of directors. Hubbard, a seasoned financial executive with a career in public accounting and auditing, will also lead the company's audit committee. Hubbard's appointment brings the board's total number of members to four.
BioPharmX Corporation Granted Pre-IND Meeting With U.S. FDA To Review Its Topical Acne Solution
PR Newswire - Mon Jan 12, 9:00AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has been granted a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration to discuss the company's topical antibiotic acne compound currently under development. The meeting, currently scheduled for March 2015, is expected to focus on the company's proposed strategy for advancing its acne program and plans for conducting safety and toxicology studies, along with human clinical trials.
BioPharmX Corporation To Present At OneMed Forum SF 2015 Conference
PR Newswire - Thu Jan 08, 9:00AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that Jim Pekarsky, chief executive officer and co-founder of BioPharmX, will present at the OneMed Forum SF 2015 Conference on Monday, January 12 at 3:00 p.m. PST at the Marriott Marquis in San Francisco.
UPM Pharmaceuticals to Manufacture BioPharmX's First Commercially Available Product
PR Newswire - Wed Dec 10, 8:00AM CST
UPM Pharmaceuticals, a division of Gregory Pharmaceutical Holdings, Inc., has reached an agreement with BioPharmX, Inc. (OTCQB: BPMX) to commercially manufacture solid dose iodine supplement tablets for the consumer products sector. The tablets will be manufactured at UPM's 475,000 square-foot manufacturing facility in Bristol, Tennessee, under a commercial supply agreement. Terms of the agreement were not disclosed.
BioPharmX unveils Violet iodine for relief of premenstrual breast discomfort and symptoms associated with Fibrocystic Breast Condition
M2 - Wed Dec 10, 6:27AM CST
Biotechnology company BioPharmX (OTCBB:BPMX) disclosed on Tuesday the market launch of its new, once-daily pill for relief of premenstrual breast discomfort, Violet iodine.
Introducing Violet(TM) Iodine, New Once-Daily, Non-Prescription Pill For Relief Of Premenstrual Breast Discomfort*
PR Newswire - Tue Dec 09, 8:37AM CST
BioPharmX Corporation (OTCQB: BPMX) today announced the availability of VioletTM iodine, a new, once-daily pill for relief of premenstrual breast discomfort. The first-of-its-kind product is based on the latest molecular iodine technology designed to help free women from the burden of breast discomfort by addressing the underlying causes of a condition known as fibrocystic breast condition (FBC), with the added benefit of promoting breast health for women of reproductive age.*
BioPharmX Corporation Announces Submission Of Pre-IND Meeting Request To The U.S. FDA For Its Topical Acne Solution
PR Newswire - Tue Dec 02, 6:30AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company's topical antibiotic acne compound currently under development. The company plans to follow up by submitting a briefing package on a later date in support of a pre-IND meeting to review the company's proposed strategy and plan for conducting safety and toxicology studies and human clinical trials required for approval of its acne product.
BiopharmX Announces Breast Health Medical Advisory Board
PR Newswire - Mon Nov 17, 7:00AM CST
BioPharmX Corporation (OTCQB: BPMX) today announced the formation of a Breast Health Medical Advisory Board (MAB) composed of highly respected physicians selected to provide a depth and range of experience in breast health. Members will serve as a strategic resource to BioPharmX as it develops products that address unmet breast health needs. Specifically, the advisory board will provide clinical trial and protocol design advice and guidance regarding emerging breast health trends and new product opportunities.
BioPharmX Corporation Announces Appointment Of Ping Wang Of Korea Investment Partners To Board Of Directors
PR Newswire - Mon Nov 10, 7:10AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced the appointment of Mr. Ping Wang, Principal of Korea Investment Partners, to the company's board of directors. Mr. Wang's appointment follows Korea Investment Partners' investment in BioPharmX as part of its Series A private placement, which was also announced today.
BioPharmX Corporation Secures Up To $12 Million In Private Placement
PR Newswire - Mon Nov 10, 7:00AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, announced that the Company has secured up to $12 million in a Series A private placement (Series A). The $12 million in total funding secured includes convertible notes previously converted to common shares, as well as the Series A private placement, which was completed in a series of closings that occurred between May 2014 and November 2014. The total amount includes $2 million in funding subject to the company achieving certain milestones. The proceeds are being used to advance the Company's pipeline of products in the fields of women's health and dermatology and to fund the near-term launch and commercialization of the Company's women's health product. The Series A private placement was led by Korea Investment Partners (KIP), which is now represented on BioPharmX's board of directors, and complemented by a combination of accredited institutional investors and high-net worth private individuals.
